KMT2A and acute myeloid leukemia: Co-treatment with LSD1i and cytarabine, DNA hypomethylating agents, or inhibitor of HDACs, FLT3, DOT1L or BCL2, was shown to exert synergistic lethality in AML expressing MLL fusion protein25,30.